Craig C. Hopkinson - Feb 22, 2023 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Stock symbol
ALKS
Transactions as of
Feb 22, 2023
Transactions value $
-$148,431
Form type
4
Date filed
2/24/2023, 07:23 PM
Previous filing
Feb 22, 2023
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +12K +24.14% 61.9K Feb 22, 2023 Direct F1
transaction ALKS Ordinary Shares Tax liability -$148K -5.35K -8.63% $27.77 56.6K Feb 22, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -12K -33.33% 24.1K Feb 22, 2023 Ordinary Shares 12K Direct F1, F2
transaction ALKS Employee Stock Option (Right to Buy) Award $0 +121K $0.00 121K Feb 23, 2023 Ordinary Shares 121K $27.36 Direct F3
transaction ALKS Restricted Stock Unit Award Award $0 +30.2K $0.00 30.2K Feb 23, 2023 Ordinary Shares 30.2K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.
F3 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.
F4 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.